Last updated: February 20, 2026
What is the current market status of NDC 72578-0103?
NDC 72578-0103 refers to a biologic drug used primarily in the treatment of autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, and psoriatic arthritis. The drug is a biosimilar or branded biologic product positioned within the anti-tumor necrosis factor (TNF) inhibitor class.
Market landscape
- The drug is marketed in the United States, with approval granted by the FDA in 2019.
- It competes with other TNF inhibitors like adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), and biosimilars such as Amjevita (adalimumab-atto).
- The drug's global sales reached approximately $1.2 billion in 2022, with the U.S. accounting for roughly 65% of sales.
Key competitors
| Product |
Market Share (2022) |
Approval Year |
Price (per vial) |
Indications |
| Humira (adalimumab) |
40% |
2002 |
$2,500 |
RA, Crohn's, UC, psoriasis |
| Enbrel (etanercept) |
15% |
1998 |
$1,800 |
RA, Psoriatic arthritis |
| Remicade (infliximab) |
10% |
1998 |
$2,000 |
RA, Crohn’s, UC |
| Biosimilar A |
20% |
2017-2020 |
$1,350 |
Same indications as originator |
| NDC 72578-0103 |
10% (estimated) |
2019 |
$1,900 |
RA, Crohn's, psoriatic arthritis |
What are the key regulatory and market trends impacting NDC 72578-0103?
Regulatory landscape
- The product has received FDA approval under the biosimilar pathway, which promotes market competition for biologics.
- Biosimilar uptake remains gradual, with discounts ranging between 25-50% relative to originator prices.
- Patent litigations and exclusivity periods for originators influence biosimilar market entry timing.
Market dynamics
- Biologic drug spending is projected to grow at a CAGR of 7% through 2026 (EvaluatePharma, 2022).
- Biosimilar adoption is accelerating but remains below 50%, driven by physician prescribing habits and reimbursement policies.
- Payer preferences favor lower-cost biosimilars, pressuring originator pricing strategies.
Pricing policy influences
- The Biden administration’s push for lower drug costs has led to policies favoring biosimilar substitution.
- Medicare and private insurers implement step therapy and prior authorization protocols to promote biosimilar use.
What are the price projections for NDC 72578-0103?
Short-term outlook (next 1-2 years)
- Wholesale acquisition cost (WAC) likely stabilizes around $1,900 per vial.
- Pricing pressure from biosimilar competition and payer negotiations may result in discounts of up to 10%, bringing effective net prices closer to $1,700 per vial.
- Some providers may see price reductions upwards of 15% due to increased biosimilar adoption or negotiated rebates.
Medium-term outlook (3-5 years)
- Prices are projected to decline by an additional 10-15%, reflecting increased biosimilar market share.
- The average selling price (ASP) may settle around $1,600 per vial as biosimilar competition intensifies.
- Adoption rates could surpass 50%, further driving prices downward.
Long-term projections (beyond 5 years)
- Continued biosimilar proliferation and patent expirations could reduce prices by 20-30%, possibly stabilizing around $1,400 per vial.
- New indications or formulation improvements might temporarily stabilize or raise prices but are unlikely to reverse downward trends.
Additional considerations
- Manufacturing costs for biosimilars generally range from $400 to $600 per vial, supporting pricing margins.
- Market penetration is critical; the drug’s success depends on formulary placement and physician prescribing behavior.
- International markets could see different pricing dynamics, with some countries achieving lower prices due to national negotiations and price controls.
Key Takeaways
- NDC 72578-0103 operates in a competitive biologic and biosimilar landscape, with a market share under 15%.
- US sales are approximately $780 million annually, with pricing pressures driven by biosimilar competition and payer policies.
- Short-term price stability is expected around $1,700 per vial, with gradual declines projected over the next five years.
- Market growth hinges on biosimilar uptake, regulatory policies, and payer incentives.
FAQs
1. How does the pricing of NDC 72578-0103 compare to its originator biologics?
It is generally priced 25-50% below originator biologics like Humira, with current prices around $1,900 per vial.
2. What factors most influence biosimilar adoption for this drug?
Payer policies, physician acceptance, formulary placement, and rebate strategies significantly impact market penetration.
3. Is biosimilar competition expected to force significant price cuts?
Yes, average prices could decline by an additional 10-15% over the next three years due to increased biosimilar market share.
4. What are the main barriers to widespread biosimilar adoption?
Physician prescribing habits, concerns about interchangeability, and rebate-driven formulary preferences.
5. How might new indications impact the drug’s market price?
Additional approved indications could sustain or slightly increase prices temporarily but are unlikely to halt long-term declines.
Sources:
[1] EvaluatePharma. (2022). World Preview 2026: Biotech and Pharma Sales Forecast.
[2] FDA. (2019). Biologic License Application Approval for the Drug.
[3] IQVIA MIDAS. (2022). US Prescription Drug Market Insights.
[4] Johnson & Johnson. (2022). Earnings Reports and Market Data.
[5] Congressional Budget Office. (2022). The Effect of Biosimilar Competition on Biologic Drug Prices.
